RESUMEN
BACKGROUND: The WHO recommends single low-dose primaquine (SLDPQ, 0.25 mg/kg body weight) in falciparum-infected patients to block malaria transmission and contribute to eliminating multidrug resistant Plasmodium falciparum from the Greater Mekong Sub region (GMS). However, the anxiety regarding PQ-induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase deficiency (G6PDd) has hindered its use. Therefore, we assessed the tolerability of SLDPQ in Cambodia to inform national policy. METHODS: This open randomised trial of dihydroartemisinin-piperaquine (DHAPP) + SLDPQ vs. DHAPP alone recruited Cambodians aged ≥1 year with acute uncomplicated P. falciparum. Randomisation was 4:1 DHAPP+SLDPQ: DHAPP for G6PDd patients and 1:1 for G6PDn patients, according to the results of the qualitative fluorescent spot test. Definitive G6PD status was determined by genotyping. Day (D) 7 haemoglobin (Hb) concentration was the primary outcome measure. RESULTS: One hundred nine patients (88 males, 21 females), aged 4-76 years (median 23) were enrolled; 12 were G6PDd Viangchan (9 hemizygous males, 3 heterozygous females). Mean nadir Hb occurred on D7 [11.6 (range 6.4 â 15.6) g/dL] and was significantly lower (p = 0.040) in G6PDd (n = 9) vs. G6PDn (n = 46) DHAPP+SLDPQ recipients: 10.9 vs. 12.05 g/dL, Δ = -1.15 (95% CI: -2.24 â -0.05) g/dL. Three G6PDn patients had D7 Hb concentrations < 8 g/dL; D7-D0 Hbs were 6.4 â 6.9, 7.4 â 7.4, and 7.5 â 8.2 g/dL. For all patients, mean (range) D7-D0 Hb decline was -1.45 (-4.8 â 2.4) g/dL, associated significantly with higher D0 Hb, higher D0 parasitaemia, and receiving DHAPP; G6PDd was not a factor. No patient required a blood transfusion. CONCLUSIONS: DHAPP+SLDPQ was associated with modest Hb declines in G6PD Viangchan, a moderately severe variant. Our data augment growing evidence that SLDPQ in SE Asia is well tolerated and appears safe in G6PDd patients. Cambodia is now deploying SLDPQ and this should encourage other GMS countries to follow suit. TRIAL REGISTRATION: The clinicaltrials.gov reference number is NCT02434952 .
Asunto(s)
Antimaláricos/administración & dosificación , Glucosa-6-Fosfato/deficiencia , Malaria Falciparum/tratamiento farmacológico , Primaquina/administración & dosificación , Adolescente , Adulto , Anciano , Artemisininas/administración & dosificación , Cambodia , Niño , Preescolar , Femenino , Deficiencia de Glucosafosfato Deshidrogenasa , Humanos , Malaria Falciparum/metabolismo , Malaria Falciparum/parasitología , Masculino , Persona de Mediana Edad , Parasitemia/tratamiento farmacológico , Parasitemia/metabolismo , Parasitemia/parasitología , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/fisiología , Adulto JovenAsunto(s)
Síndrome de Alstrom/diagnóstico , Metahemoglobinemia/etiología , Osteocondritis Disecante/diagnóstico , Artralgia/etiología , Niño , Preescolar , Femenino , Glucosa-6-Fosfato/deficiencia , Humanos , Masculino , Metahemoglobinemia/diagnóstico , Leucemia-Linfoma Linfoblástico de Células T Precursoras , Astrágalo , Urato Oxidasa/efectos adversosRESUMEN
A 14-year-old male child presented with microcytosis, a known alpha(+)-thalassemia (alpha-thal) heterozygote and a hemizygous glucose-6-phosphate dehydrogenase (G6PD) deficiency. Furthermore, cation exchange high performance liquid chromatography (HPLC) revealed an additional peak eluting slightly before Hb A. The peak area of the variant was equal to that of Hb A, suggesting a beta-globin variant. Matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS) analysis confirmed the mutation at the protein level. The variant was detectable by isoelectric focusing (IEF) or by reversed phase HPLC. DNA sequencing revealed a heterozygous mutation at codon 135 of the beta gene, already described as Hb Alperton. Hb Alperton showed decreased oxygen affinity. Neither biochemical nor clinical characteristics for Hb Alperton have been reported so far.
Asunto(s)
Hemoglobinas Anormales/metabolismo , Oxígeno/metabolismo , Globinas beta/genética , Adolescente , Glucosa-6-Fosfato/deficiencia , Hemoglobinas Anormales/genética , Heterocigoto , Humanos , Masculino , Análisis de Secuencia de ADN , Talasemia alfa/genética , Talasemia alfa/metabolismoRESUMEN
Data are presented on the urinary corticosteroid metabolic profile of the mouse strain 129/svJ. Through the use of GC/MS we have characterized, or tentatively identified corticosterone (Kendall's compound B) metabolites of both the 11beta-hydroxy and 11-carbonyl (compound A) series in urine. Full mass spectra of the methyloxime-trimethylether derivatives of 15 metabolites are included in the paper as an aid to other researchers in the field. Metabolites ranged in polarity from tetrahydrocorticosterone (THB) to dihydroxy-corticosterone with dominance of highly polar steroids. We found that prior to excretion corticosterone can undergo oxidation at position 11beta, reduction at position 20 and A-ring reduction. Metabolites retaining the 3-oxo-4-ene structure can be hydroxylated at position 6beta- as well as at an unidentified position, probably 16alpha-. Saturated steroids can be hydroxylated at positions 1beta-, 6alpha-, 15alpha- and 16alpha. A pair of hydroxy-20-dihydro-corticosterone metabolites (OH-DHB) were the most important excretory products accounting for about 40% of the total. One metabolite of this type was identified as 6beta-hydroxy-DHB; the other, of similar quantitative importance was probably 16alpha-hydroxy-DHB. The ratio of metabolites of corticosterone (B) to those of 11-dehydro-corticosterone (A) was greater than 9:1, considerably higher than that for the equivalent "human" ratio of 1:1 for cortisol to cortisone metabolites. Results from this study allowed the evaluation of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) activity in mice with deleted glucose-6-phosphate transporter (G6PT). These mice had attenuated back-conversion of A to B resulting in an increased ratio of A-metabolites to B-metabolites [Walker EA, Ahmed A, Lavery GG, Tomlinson JW, Kim SY, Cooper MS, Stewart PM, 11beta-Hydroxysteroid dehydrogenase type 1 regulation by intracellular glucose-6-phosphate, provides evidence for a novel link between glucose metabolism and HPA axis function. J Biol Chem 2007;282:27030-6]. We believe this study is currently the most comprehensive on the urinary steroid metabolic profile of the mouse. Quantitatively less steroid is excreted in urine than in feces by this species but urine analysis is more straightforward and the hepatic metabolites are less subject to microbial degradation than if feces was analyzed.
Asunto(s)
Corticosterona/metabolismo , Corticosterona/orina , Glucosa-6-Fosfato/metabolismo , Esteroides/metabolismo , Esteroides/orina , Animales , Corticosterona/análisis , Corticosterona/química , Femenino , Cromatografía de Gases y Espectrometría de Masas , Glucosa-6-Fosfato/deficiencia , Glucosa-6-Fosfato/genética , Hidroxiesteroide Deshidrogenasas/análisis , Hidroxiesteroide Deshidrogenasas/química , Hidroxiesteroide Deshidrogenasas/metabolismo , Hidroxiesteroide Deshidrogenasas/orina , Masculino , Ratones , Ratones Endogámicos , Estructura Molecular , Esteroides/análisis , Esteroides/químicaRESUMEN
Glycogen storage disease type I (GSD-I) is a group of autosomal recessive disorders with an incidence of 1 in 100,000. The two major subtypes are GSD-Ia, caused by a deficiency of glucose-6-phosphatase (G6Pase), and GSD-Ib, caused by a deficiency of glucose-6-phosphate transporter (G6PT). We report that a substantial improvement was achieved following several infusions of hepatocytes in a patient with GSD-Ib. Hepatocytes were isolated from the unused cadaveric whole livers of two donors. At the first transplantation, approximately 2 x 10(9) cells (2% of the estimated recipient's total hepatocytes) were infused. Seven days later 1 x 10(9) (1% of liver mass) cryopreserved hepatocytes from the same donor were infused, and an additional 3 x 10(9) (3% of liver mass) cells from the second donor were infused 1 month after the second transplantation. After the hepatocyte transplantation, the patient showed no hypoglycemic symptoms despite the discontinuation of cornstarch meals. Liver biopsies on posttransplantation days 20 and 250 showed a normal level of glucose-6-phosphatase activity in presolubilization assay that was very low before transplantation. This was the first and successful clinical hepatocyte transplantation in Korea. In this study, hepatocyte transplantation allowed a normal diet in a patient with GSD-Ib, with substantial improvement in their quality of life. Hepatocyte transplantation might be an alternative to liver transplantation and dietary therapy in GSD-Ib.
Asunto(s)
Glucosa-6-Fosfatasa/metabolismo , Glucosa-6-Fosfato/metabolismo , Enfermedad del Almacenamiento de Glucógeno Tipo I/metabolismo , Enfermedad del Almacenamiento de Glucógeno Tipo I/terapia , Hepatocitos/trasplante , Adolescente , Cadáver , Estudios de Seguimiento , Glucosa-6-Fosfato/deficiencia , Enfermedad del Almacenamiento de Glucógeno Tipo I/patología , Hepatocitos/enzimología , Humanos , Inmunosupresores/uso terapéutico , Corea (Geográfico) , Hígado/citología , Hígado/inmunología , Masculino , Calidad de Vida , Inmunología del Trasplante/efectos de los fármacos , Trasplantes , Resultado del TratamientoRESUMEN
The type I glycogen storage diseases (GSD-I) are a group of related diseases caused by a deficiency in the glucose-6-phosphatase-alpha (G6Pase-alpha) system, a key enzyme complex that is essential for the maintenance of blood glucose homeostasis between meals. The complex consists of a glucose-6-phosphate transporter (G6PT) that translocates glucose-6-phosphate from the cytoplasm into the lumen of the endoplasmic reticulum, and a G6Pase-alpha catalytic unit that hydrolyses the glucose-6-phosphate into glucose and phosphate. A deficiency in G6Pase-alpha causes GSD type Ia (GSD-Ia) and a deficiency in G6PT causes GSD type Ib (GSD-Ib). Both GSD-Ia and GSD-Ib patients manifest a disturbed glucose homeostasis, while GSD-Ib patients also suffer symptoms of neutropenia and myeloid dysfunctions. G6Pase-alpha and G6PT are both hydrophobic endoplasmic reticulum-associated transmembrane proteins that can not expressed in soluble active forms. Therefore protein replacement therapy of GSD-I is not an option. Animal models of GSD-Ia and GSD-Ib that mimic the human disorders are available. Both adenovirus- and adeno-associated virus (AAV)-mediated gene therapies have been evaluated for GSD-Ia in these model systems. While adenoviral therapy produces only short term corrections and only impacts liver expression of the gene, AAV-mediated therapy delivers the transgene to both the liver and kidney, achieving longer term correction of the GSD-Ia disorder, although there are substantial differences in efficacy depending on the AAV serotype used. Gene therapy for GSD-Ib in the animal model is still in its infancy, although an adenoviral construct has improved the metabolic profile and myeloid function. Taken together further refinements in gene therapy may hold long term benefits for the treatment of type I GSD disorders.
Asunto(s)
Terapia Genética/métodos , Enfermedad del Almacenamiento de Glucógeno Tipo I/terapia , Adenoviridae/genética , Vectores Genéticos , Glucosa-6-Fosfatasa/genética , Glucosa-6-Fosfato/deficiencia , HumanosAsunto(s)
Glucosa-6-Fosfato/deficiencia , Hemoglobinuria/inducido químicamente , Hemólisis , Vitaminas/efectos adversos , Transfusión Sanguínea , Femenino , Hemoglobinuria/complicaciones , Hemoglobinuria/terapia , Humanos , Persona de Mediana Edad , Esclerosis Múltiple/sangre , Esclerosis Múltiple/complicaciones , Esclerosis Múltiple/terapiaRESUMEN
The prevalence of non insulin dependent diabetes mellitus (NIDDM) is increasing in all populations. This increment has been correlated with changes in lifestyle, particularly in eating behavior. Migration studies strongly suggest that NIDDM becomes more common when lifestyle factors interact with genetic susceptibility. Blacks have a higher prevalence of NIDDM than whites. In this study, it is suggested that persistent hyperglycemia mediated through the main carbohydrate of the Western diet-wheat, as white flour and whole wheat-in combination with partial or complete glucose 6-phosphate dehydrogenase deficiency are possible factors for the higher prevalence of NIDDM in blacks.
Asunto(s)
Negro o Afroamericano , Diabetes Mellitus Tipo 2/etnología , Carbohidratos de la Dieta/administración & dosificación , Diabetes Mellitus Tipo 2/genética , Diabetes Mellitus Tipo 2/metabolismo , Glucosa-6-Fosfato/deficiencia , Productos Finales de Glicación Avanzada/sangre , Humanos , Hiperglucemia/etnología , Hiperglucemia/metabolismo , Hipertensión/etnología , Hipertensión/metabolismo , Prevalencia , Factores de RiesgoRESUMEN
After ingesting fava beans, a 26-month-old Chinese-Japanese male infant showed a sickly complexion and yellowish-brownish skin and was hospitalized. Severe hemolytic anemia was observed on admission, and transfusion of 200 ml of packed red cells was required. Red cell enzyme assay revealed that the patient and the mother were deficient in glucose-6-phosphate dehydrogenase (G6PD). Subsequent molecular analysis showed that the patient had a missense mutation 1376 G to T (G6PD Canton) and his mother was a homozygote for the mutation. The patient was a son of a Chinese (Taiwanese) mother and a Japanese father. Although G6PD deficiency is rare in the original Japanese population, the number of "imported" cases could be rising rapidly. This is the first reported Japanese case of G6PD deficiency with G6PD Canton.
Asunto(s)
Favismo/genética , Glucosa-6-Fosfato/deficiencia , Secuencia de Aminoácidos , Anemia Hemolítica/etiología , Preescolar , China , Glucosa-6-Fosfato/genética , Humanos , Japón/epidemiología , Masculino , Mutación Missense , Polimorfismo Conformacional Retorcido-Simple , Taiwán/etnologíaRESUMEN
A case of neonatal kernicterus due to glucose-6-phosphate dehydrogenase deficiency (G6PD) is described. Diagnosis was delayed as the primary healthcare attendant had no knowledge of this condition and its potential to cause rapidly escalating levels of bilirubin and as she was reassured by the lack of signs of systemic illness or anaemia. The baby has been left deaf, blind, intellectually handicapped, epileptic and paralysed due to athetoid cerebral palsy. The re-organization of perinatal care in New Zealand, which has led to neonates sometimes being managed solely by primary healthcare attendants with minimal training in paediatrics may have increased the risk of a late diagnosis of potentially devastating diseases such as this.
Asunto(s)
Errores Diagnósticos , Glucosa-6-Fosfato/deficiencia , Kernicterus/diagnóstico , Bilirrubina/sangre , Humanos , Recién Nacido , Kernicterus/etiología , Masculino , Errores Innatos del Metabolismo/diagnóstico , Partería , Nueva Zelanda , Alta del PacienteRESUMEN
BACKGROUND: Glucose-6-phosphate dehydrogenase deficiency, one of the most common human enzymatic defects, is characterized by extreme molecular and biochemical heterogeneity. The molecular bases of almost all polymorphic italian variants have now been identified and the overall heterogeneity is lower than expected from biochemical data. METHODS: We examined 161 G6PD-deficient subjects (130 males and 31 females) originating from different parts of Italy. G6PD activity and molecular characterization were determined in all the subjects analyzed. RESULTS: We found the G6PD Mediterranean genotype in roughly 70%, G6PD Union and G6PD Seattle in about 6% and G6PD A- in 4% of the samples analyzed. G6PD S. Antioco and G6PD Cosenza were less frequent (1.2%), and single cases of G6PD Partenope and G6PD Tokyo were also detected. CONCLUSIONS: We report the frequency and distribution of the most common G6PD variants in Italy. Greater molecular heterogeneity than described by others was observed, especially in Sardinia. Among the severe deficient variants, G6PD Mediterranean has a higher prevalence in Sardinia (83%) than in continental Italy (61%), as does G6PD Union (10% and 4%, respectively). G6PD Seattle and A-, associated with mild G6PD deficiency, are by contrast more frequent in continental Italy.